
    
      This is a prospective, randomized, double-blind, double-dummy and placebo-controlled study in
      individuals with disabling migraine. The participants will be randomized to receive
      Rizatriptan + Naproxen (10/550mg), Rizatriptan (10mg), Naproxen (550mg) or placebo.
    
  